Acadian Asset Management
HRMY icon

Acadian Asset Management’s Harmony Biosciences HRMY Stock Holding History

Acadian Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Buy
130,749
+108,209
+480% +$3.55M 0.01% 786
2025
Q4 		$841K Sell
22,540
-25,663
-53% -$844K ﹤0.01% 1158
2025
Q3 		$1.32M Buy
48,203
+26,026
+117% +$897K ﹤0.01% 987
2025
Q2 		$699K Sell
22,177
-116,298
-84% -$3.74M ﹤0.01% 1065
2025
Q1 		$4.59M Buy
+138,475
New +$4.96M 0.01% 525
2024
Q4 		– Sell
-4,819
Closed -$192K – 1862
2024
Q3 		$192K Buy
+4,819
New +$169K ﹤0.01% 1382
2022
Q4 		– Sell
-2,724
Closed -$120K – 1840
2022
Q3 		$120K Hold
2,724
– – ﹤0.01% 1323
2022
Q2 		$133K Sell
2,724
-643
-19% -$28.9K ﹤0.01% 1293
2022
Q1 		$163K Buy
3,367
+1,383
+70% +$56.4K ﹤0.01% 1254
2021
Q4 		$84K Buy
+1,984
New +$79.1K ﹤0.01% 1411

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Acadian Asset Management's HRMY Position: Q1 2026 in Review

Acadian Asset Management increased its Harmony Biosciences (HRMY) stake by 480% in Q1 2026, buying an estimated $3.55M and bringing the position to 130,749 shares worth $3.65M. The position accounts for 0.01% of the portfolio, ranked #786.

Acadian Asset Management first reported a position in HRMY in Q4 2021 and has held it in 10 quarters since. The position peaked at $4.59M in Q1 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Acadian Asset Management held 130,749 shares of Harmony Biosciences worth $3.65M as of Q1 2026.
  • Acadian Asset Management bought 108,209 Harmony Biosciences shares in Q1 2026, an estimated $3.55M.
  • Harmony Biosciences made up 0.01% of Acadian Asset Management's portfolio in Q1 2026, its #786 holding.
  • Acadian Asset Management first reported a position in Harmony Biosciences in Q4 2021 and has held it in 10 quarters since.
  • Acadian Asset Management's Harmony Biosciences position peaked at $4.59M in Q1 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.